Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Deferred Taxes (2015 - 2021)

ImmunityBio (IBRX) reported Deferred Taxes of -$8000.0 for Q4 2021, up 96.14% year-over-year from -$4078.8 in Q4 2020, and up 96.14% on a QoQ basis from -$207000.0 in Q4 2020.

ImmunityBio (IBRX) has 7 years of Deferred Taxes data on file, last reported at -$8000.0 in Q4 2021.

  • Quarterly Deferred Taxes rose 96.14% year-over-year to -$8000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$8000.0 (up 99.73% YoY) and the FY2022 annual result came in at -$4000.0, up 50.0% from the prior year.
  • Deferred Taxes improved to -$8000.0 in Q4 2021 per IBRX's latest filing, from -$207000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $38000.0 in Q2 2020 and bottomed at -$1.7 million in Q3 2020.
  • The 5-year median for Deferred Taxes is -$124000.0 (2017), against an average of -$282071.4.
  • The widest annual swing landed in 2020, when Deferred Taxes tumbled 2487.5%; it then surged 96.14% in 2021.
  • Tracing IBRX's Deferred Taxes over 5 years: stood at -$182000.0 in 2017, then jumped by 32.97% to -$122000.0 in 2018, then jumped by 93.44% to -$8000.0 in 2019, then plunged by 2487.5% to -$207000.0 in 2020, then surged by 96.14% to -$8000.0 in 2021.
  • Per Business Quant, the three latest IBRX Deferred Taxes figures stand at -$8000.0 (Q4 2021), -$207000.0 (Q4 2020), and -$1.7 million (Q3 2020).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -859,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -65.30 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 96.00 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 9.31 Mn
10 ImmunityBio 7.72 Bn 7.34 Bn 43.97 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 -8,000.00
Dec 31, 2020 -207,000.00
Sep 30, 2020 -1.70 Mn
Jun 30, 2020 38,000.00
Mar 31, 2020 -1.07 Mn
Dec 31, 2019 -8,000.00
Dec 31, 2018 -122,000.00
Sep 30, 2018 -128,000.00
Jun 30, 2018 -124,000.00
Mar 31, 2018 -124,000.00
Dec 31, 2017 -182,000.00
Sep 30, 2017 -98,000.00
Jun 30, 2017 -124,000.00
Mar 31, 2017 -93,000.00
Dec 31, 2016 -152,000.00
Sep 30, 2016 -50,000.00
Jun 30, 2016 -228,000.00
Mar 31, 2016 -145,000.00
Dec 31, 2015 -302,000.00